Ocheni Sunday, Zabelina Tatjana, Bacher Ulrike, Ayuk Francis, Zander Axel, Kröger Nicolaus
Department for Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Leuk Lymphoma. 2009 Apr;50(4):612-8. doi: 10.1080/10428190902777442.
We compared a single, subcutaneous fixed dose of 6 mg pegfilgrastim on day +5 with daily lenograstim 263 microg from day +5 and continued until neutrophils were >or=0.5 x 10(9)/L after allogeneic peripheral blood stem-cell transplantation (PBSCT) from unrelated donors for various hematological disorders. Neutrophil engraftment was significantly faster (p = 0.006) in the pegfilgrastim than in the lenograstim group. There was also a tendency towards achieving a faster platelet engraftment (p = 0.06) in the pegfilgrastim group (median 16 vs. 19 days). The duration of thrombocytopenia (<20 x 10(9)/L) was shorter in the pegfilgrastim group (p = 0.05). There were no significant differences in the duration of neutropenia (p = 0.14) and febrile neutropenia (p = 0.25). Differences were not observed in the treatment related mortality, disease free and overall survival between both groups. We conclude that Pegfilgrastim ensured rapid neutrophil engraftment after unrelated allogeneic peripheral SCT, which was at least as effective as daily lenograstim.
我们比较了在异基因外周血干细胞移植（PBSCT）治疗各种血液系统疾病后，于第+5天皮下注射单次固定剂量6毫克培非格司亭与从第+5天开始每日注射263微克来格司亭直至中性粒细胞≥0.5×10⁹/L的情况。培非格司亭组中性粒细胞植入明显更快（p = 0.006），优于来格司亭组。培非格司亭组在血小板植入方面也有更快的趋势（p = 0.06）（中位时间分别为16天和19天）。培非格司亭组血小板减少症（<20×10⁹/L）的持续时间更短（p = 0.05）。两组在中性粒细胞减少症持续时间（p = 0.14）和发热性中性粒细胞减少症持续时间（p = 0.25）方面无显著差异。两组在治疗相关死亡率、无病生存率和总生存率方面未观察到差异。我们得出结论，培非格司亭可确保无关供者异基因外周血干细胞移植后中性粒细胞快速植入，其效果至少与每日注射来格司亭一样有效。
